Literature DB >> 10669784

Implications of the S-shaped domain in the quaternary structure of human arginase.

A Mora1, M del Ara Rangel, J M Fuentes, G Soler, F Centeno.   

Abstract

Arginase I is a homotrimeric protein with a binuclear manganese cluster. At the C-terminus of each monomer, the polypeptide chain forms an unusual S-shaped oligomerization motif where the majority of intermonomer contacts are located [Z.F. Kanyo, L.R. Scolnick, D.E. Ash, D.W. Christianson, Nature 383 (1996) 554-557]. In order to study the implication of this motif in the quaternary structure of human arginase I, we have constructed a truncated arginase lacking the 14 C-terminal amino acids, leaving Arg-308 as the last residue in the sequence. The resulting protein retains its trimeric structure, as determined by gel filtration (molecular mass 94 kDa). The same result was obtained in the presence of high ionic strength (KCl 0.5 M). Both data indicate that neither the S-shaped motif nor Arg-308 are fundamental in keeping the trimeric quaternary structure. Data obtained from intrinsic anisotropy and fluorescence intensity studies allow us to predict that the distance between the two unique tryptophans in the sequence is 2.9 nm in the native arginase and 4.1 nm for the truncated mutant. These distances allow us to assume a different conformational state in the truncated arginase without any change in its quaternary structure, suggesting that the carboxy-terminal motif is not the most prominent domain implicated in the quaternary structure of human arginase. Collisional quenching studies reinforce this possibility, since using I(-) as quenching molecule we were able to distinguish the two tryptophans in the truncated arginase. Moreover, kinetic studies show that the truncated mutant was fully active. In summary, the main conclusion about the structure of the human arginase I, derived from our study, is that the C-terminal S-shaped motif is not basic to the maintenance of the quaternary structure nor to the activity of the protein.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10669784     DOI: 10.1016/s0167-4838(99)00256-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Crystal structure of human arginase I complexed with thiosemicarbazide reveals an unusual thiocarbonyl mu-sulfide ligand in the binuclear manganese cluster.

Authors:  Luigi Di Costanzo; Michael E Pique; David W Christianson
Journal:  J Am Chem Soc       Date:  2007-05-01       Impact factor: 15.419

Review 2.  Arginase and vascular aging.

Authors:  Lakshmi Santhanam; David W Christianson; Daniel Nyhan; Dan E Berkowitz
Journal:  J Appl Physiol (1985)       Date:  2008-08-21

3.  Crystal structure of human arginase I at 1.29-A resolution and exploration of inhibition in the immune response.

Authors:  Luigi Di Costanzo; Guadalupe Sabio; Alfonso Mora; Paulo C Rodriguez; Augusto C Ochoa; Francisco Centeno; David W Christianson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

4.  Probing the specificity determinants of amino acid recognition by arginase.

Authors:  Ekaterina Y Shishova; Luigi Di Costanzo; Francis A Emig; David E Ash; David W Christianson
Journal:  Biochemistry       Date:  2009-01-13       Impact factor: 3.162

Review 5.  Evolution of the arginase fold and functional diversity.

Authors:  D P Dowling; L Di Costanzo; H A Gennadios; D W Christianson
Journal:  Cell Mol Life Sci       Date:  2008-07       Impact factor: 9.261

6.  Expression, purification, assay, and crystal structure of perdeuterated human arginase I.

Authors:  Luigi Di Costanzo; Martine Moulin; Michael Haertlein; Flora Meilleur; David W Christianson
Journal:  Arch Biochem Biophys       Date:  2007-05-21       Impact factor: 4.013

7.  Crystal structure of Schistosoma mansoni arginase, a potential drug target for the treatment of schistosomiasis.

Authors:  Yang Hai; Jennifer E Edwards; Michael C Van Zandt; Karl F Hoffmann; David W Christianson
Journal:  Biochemistry       Date:  2014-07-09       Impact factor: 3.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.